Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ENvue Medical's revenue for the
three
months ended in Jun. 2026 was €0.21 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was €1.65 Mil.
ENvue Medical's Revenue per Share for the
three
months ended in Jun. 2026 was €0.40.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €13.90.
Warning Sign:
ENvue Medical Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of ENvue Medical was -97.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -59.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -29.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, ENvue Medical's highest 3-Year average Revenue per Share Growth Rate was 54.20% per year. The lowest was -59.70% per year. And the median was -9.00% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
ENvue Medical Revenue Related Terms
ENvue Medical Revenue Historical Data
* Premium members only.
The historical data trend for ENvue Medical's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, ENvue Medical's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENvue Medical Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ENvue Medical's Revenue distribution charts can be found below:
* The bar in red indicates where ENvue Medical's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENvue Medical (FRA:56R) has a Revenue of €1.65 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on ENvue Medical and its competitors.
Is ENvue Medical's Revenue too high?
ENvue Medical's current Revenue is €1.65 Mil. Overall, ENvue Medical has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does ENvue Medical's Revenue compare to RMSL and GCTK?
ENvue Medical's Revenue of €1.65 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on ENvue Medical and its competitors. ENvue Medical's current Revenue is €1.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENvue Medical stock overvalued right now?
ENvue Medical (FRA:56R) has a current Revenue of €1.65 Mil. The stock's GF Value™ is €99.08, compared to a current price of €74.40 — trading 24.9% below its estimated fair value. The current Revenue is €1.65 Mil. ENvue Medical's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For ENvue Medical (FRA:56R), the current Revenue is €1.65 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ENvue Medical (FRA:56R) Overvalued in 2026?
Based on GuruFocus' analysis, ENvue Medical stock appears to be undervalued.
The current stock price of €74.40 is trading 24.9% below its estimated GF Value™ of €99.08.
Key valuation signals for FRA:56R:
Revenue: €1.65 Mil
GF Value™: €99.08 vs. price of €74.40 (24.9% below fair value)
No single metric tells the full story. See the FRA:56R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ENvue Medical Inc develops medical devices for enhanced navigation in clinical procedures. The company provides personalized navigation technology to assist clinicians in placing feeding tubes safely and efficiently. Its ENvue system uses smart feeding tubes with sensors, body mapping, and continuous visual guidance to confirm accurate positioning and reduce complications like lung misplacement. The company conducted the business through two primary operating segments: NanoVibronix and ENvue. The firm generates the majority of its revenue from NanoVibronix, which derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its Systems and Nasoenteral tubes.
46GF Score
Get the complete analysis for FRA:56R
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:56R has been successfully added to your 
